Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Classical hematology 2

Conditions

Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 2Anemia, Refractory, with Excess of Blasts 2Pancreatic Neoplasms 1Cytopenia 1

Interventions

Cytarabine 6Thioguanine 4Methotrexate 4Idarubicin 4Etoposide 4Daunorubicin 4Azacitidine 4Peripheral Blood Stem Cell Transplantation 3Early Intervention, Educational 3Decitabine 3Cyclophosphamide 3liposomal amphotericin B 2decitabine and cedazuridine drug combination 2Therapeutics 2Radiotherapy 2Psychiatric Rehabilitation 2ON 01910 2Mitoxantrone 2Hydrocortisone 2Filgrastim 2Dexamethasone 2Busulfan 2Biopsy 2Asparaginase 2valspodar 1sabatolimab 1pevonedistat 1palmitoyl-L-asparaginase 1merphos 1lonafarnib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Leukemia, Myelomonocytic, Chronic × ON 01910 × Clear all
NCT01241500 2020-06-30

ONTIME

Traws Pharma, Inc.

Phase 3 Completed
299 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT01928537 2020-06-30

Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine

Traws Pharma, Inc.

Phase 3 Completed
67 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Cytopenia, Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡